ISOLATED NUCLEIC ACID MOLECULE WHICH CODES FOR A TUMOR REJECTION ANTIGEN PRECURSOR, AND USES THEREOF

Abstract: A nucleic acid molecule which codes for a tumor antigen precursor which is in turn processed to antigens presented by an HLA molecule is described. The HLA molecule may be HLA-A2, HLA-A28, HLA-B13, HLA-B44 or HLA-Cw6. The antigens are also described. These materials are useful in diagnostic and therapeutic methodologies. The tumor rejection antigen precursor is not tyrosinase, which has been previously identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44. The figure sets forth data regarding cytolytic activity of lymphocytes obtained in autologous mixed lymphocyte-tumor cell cultures.

Description: ISOLATED NUCLEIC ACID MOLECULE WHICH CODES FOR A TUMOR REJECTIO ANTIGEN PRECURSOR, AND USES THEREOF RELATED APPLICATION This application is a continuation-in-part of copending application Serial No. 08/253,503 filed June 3, 1994, incorporated by reference. FIELD OF THE INVENTION This invention relates to isolated peptides, derived from tumor rejection antigen precursors and presented by HLA molecules, such as HLA-A24, HLA-A28, HLA-B13, HLA-B44, and HLA-Cw6 molecules and uses thereof. In addition, it relates to the ability to identify those individuals diagnosed with conditions characterized by cellular abnormalities whose abnormal cells present complexes of these peptides and HLA molecules, the presented peptides, and the ramifications thereof. Also a part of the invention are the nucleic acid molecules which code for the tumor rejection antigen precursor, the tumor rejection antigen precursor, and uses thereof. BACKGROUND AND PRIOR ART The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA")/ or major histocompatibility complexes ("MHCs"), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cell and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Recently, much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, Science 257: 880 (1992); Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latron et al. , Science 257: 964 (1992). The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992, published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs. The genes are said to code for "tumor rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom are referred to as "tumor rejection antigens" or "TRAs". See Traversari et al. , Im unogenetics 35: 145 (1992); van der Bruggen et al. , Science 254: 1643 (1991), for further information on this family of genes. In U.S. patent application Serial Number 938,334, the disclosure of which is incorporated by reference, nonapeptideε are taught which bind to the HLA-A1 molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue. The enzyme tyrosinase catalyzes the reaction converting tyrosine to dehydroxyphenylalanine or "DOPA" and appears to be expressed selectively in melanocytes (Muller et al., EMBO J 7: 2715 (1988)). An early report of cDNA for the human enzyme is found in Kwon, U.S. Patent No. 4,898,814. A later report by Bouchard et al., J. Exp. Med. 169: 2029 (1989) presents a slightly different sequence. A great deal of effort has gone into identifying inhibitors for this enzyme, as it has been implicated in pigmentation diseases. Some examples of this literature include Jinbow, WO9116302; Mishima et al., U.S. Patent No. 5,077,059, and Nazzaropor, U.S. Patent No. 4,818,768. The artisan will be familiar with other references which teach similar materials. U.S. Patent Application 08/081,673, filed June 23, 1993 and incorporated by reference, teaches that tyrosinase may be treated in a manner similar to a foreign antigen or a TRAP molecule - i.e., it was found that in certain cellular abnormalities, such as melanoma, tyrosinase is processed and a peptide derived therefrom forms a complex with HLA molecules on certain abnormal cells. These complexes were found to be recognized by cytolytic T cells ("CTLs"), which then lyse the presenting cells. The ramifications of this surprising and unexpected phenomenon were discussed. Additional peptides have now been found which also act as tumor rejection antigens presented by HLA-A2 molecules. These are described in Serial No. 08/203,054, filed February 28, 1994 and incorporated by reference. U.S. Patent Application Serial No. 08/233,305 filed April 26, 1994 and incorporated by reference, disclosed that tyrosinase is also processed to an antigen presented by HLA- B44 molecules. The finding was of importance, because not all individuals are HLA-A2 * . The fact that tyrosinase is processed to an HLA-B44 presented peptide, however, does not provide for a universal approach to diagnosis and treatment of all HLA-B44* tumors, because tyrosinase expression is not universal. Further, the fact that tyrosinase is expressed by normal cells as well as tumor cells may suggest some caution in the therapeutic area. It has now been found that a non-tyrosinase coding gene also expresses a tumor rejection antigen precursor which is processed to at least one tumor rejection antigen presented by HLA-B44 molecules and to other antigens presented by HLA-A24, HLA-B13, HLA-CW6 and HLA-A28. This, inter alia, is the subject of the invention disclosure which follows. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows the results of chromium release assays using each of three different cell lines (LB33-MELcl, LB33 EBV-B, and K562), and cytolytic T cell clone 159/5. The data are presented in terms of effector/target ratios vs % of lysis. Figure 2 shows the result of lysis studies which identified cell variants "A-" "B-", and "A-,B _ ". Again, a chromium release assay was used. Cell line LB33-MELcl is A + B + , as is indicated by the positive lysis with both CTL lines tested. CTL 159/93 is anti-A, while CTL 159/5 is anti-B. Figure 3 shows results obtained when the variant A " B " was transfected with coding sequences for each of HLA-A28, HLA- B44, and HLA-Cw7, as compared to a control line. The results are depicted in terms of the sensitive TNF release assay (pg/ml), where CTL 159/5 was used. Figure 4 shows TNF release by CTL 195/5, where COS cells were transfected with HLA-B44, or HLA-B44 plus a nucleic acid molecule in accordance with this invention. Figure 5A depicts 51 Cr release in EBV-B cells, when contacted with CTL 159/5. Figure 5B is similar, but uses LB33-MEL B " cells. In each of figures 5A and 5B, the antigenic peptide of the invention was contacted to the cells prior to contact with the CTLε. Figure 6 shows the lytic activity of various autologous CTL clones on antigen loss variants derived from melanoma clonal line LB33.MEL.A-1. Figure 7 presents results showing expression of HLA-A24, A28 and B13 molecules by antigen loss variants of LB33-MEL.A- 1. Tumor cells had been incubated with mouse antibodies against particular HLA molecules, and were then labeled with fluoreεcein tagged goat anti-mouse antibodies. Figure 8 shows the production of tumor necrosis factor (TNF) by CTL clones stimulated by antigen loss variants, transfected with various HLA alleles. Untransfected LB33- MEL.A-1 cells were used as controls, as were antigen loss variants. The CTL clones used were 159/3, 159/5 and 204/26, corresponding to anti-A, anti-B, and anti-C CTLε, respectively. Figure 9 εets forth data regarding cytolytic activity of lymphocytes obtained in autologous mixed lymphocyte-tumor cell cultures. The blood mononuclear cells had been isolated from patient LB33 in either March 1990 or January 1994. The cell line LB33-MEL.A had been obtained following surgery in 1988. Cell line LB33-MEL.B was obtained from a metastasis which developed in the patient in 1993. Figure 10A depicts the lytic activity of anti-E CTL clone LB33-CTL-269/1 on autologous melanoma cellε, while figure 10B shows production of TNF by the same CTL clone, following stimulation by LB33-MEL.B-1 cellε. The εtimulator cells (10,000/microwell) had been incubated for 16 hours with 3000 CTLs. The concentration of TNF released by the CTLs had been measured using TNF senεitive WEHI-164cl3 cellε. Anti HLA-A24 monoclonal antibody C7709A2 waε used to inhibit CTL stimulation, by adding a 1/100 dilution of aεciteε fluid obtained from mice inoculated with the hybridoma cellε. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Example 1 Melanoma cell line LB33-MEL which haε been available to reεearcherε for many yearε, waε used in the following SUBSTITUTESHEETiRULE26) experiments. A clone derived therefrom was also used. The clone is referred to hereafter as LB33-MELcl. Samples containing mononuclear blood cells were taken from patient LB33. The melanoma cell line was contacted to the mononuclear blood cell containing samples. The mixtures were observed for lysis of the melanoma cell lines, this lysis indicating that cytolytic T cells ("CTLs") specific for a complex of peptide and HLA molecule preεented by the melanoma cells were present in the sample. The lysis assay employed was a chromium release assay following Herin et al. , Int. J. Cancer 39:390-396 (1987), the discloεure of which iε incorporated by reference. The assay, however, is described herein. The target melanoma cells were grown in vitro, and then resuspended at 10 7 cells/ml in DMEM, supplemented with 10 mM HEPES and 30% FCS (i.e., from fetal calf serum) and incubated for 45 minutes at 37°C with 200 μCi/ml of Na( 51 Cr)0 4 . Labelled cells were washed three times with DMEM, supplemented with 10 mM Hepes. These were then resuspended in DMEM supplemented with 10 mM Hepes and 10% FCS, after which 100 ul aliquots containing 10 3 cells, were distributed into 96 well microplates. Samples of PBLs were added in 100 ul of the same medium, and aεεayε were carried out in duplicate. Plates were centrifuged for 4 minutes at lOOg, and incubated for four hours at 37°C in a 5.5% C0 2 atmosphere. Plates were centrifuged again, and 100 ul aliquots of supernatant were collected and counted. Percentage of 51 Cr release was calculated as follows: % 51 Cr release = (ER-SR) x 100 (MR-SR) where ER is observed, experimental 51 Cr release, SR is spontaneouε releaεe meaεured by incubating 10 3 labeled cells in 200 ul of medium alone, and MR is maximum release, obtained by adding 100 ul 0.3% Triton X-100 to target cells. * Those mononuclear blood samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology. The εame method waε uεed to test target K562 cells. When EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS. These experiments led to isolation of CTL clones LB33- CTL-159/5. Figure 1 shows that this clone lysed tumor cellε, but not EBV-B cellε, or K562 cells. Following the same protocol, a second CTL clone, i.e., LB33-CTL-159/3 was isolated. These lines will be referred to as "159/5" and "159/3", respectively. This second CTL has specificity differing from 159/5. This was ascertained following isolation of two antigen losε variants which (i) are lysed by 159/5 but not 159/3 and (ii) are not lysed by 159/5 and are lysed by 159/3. These variantε are referred to aε A ~ and B " , respectively. The A" variant was then immunoselected with 159/5, and a third variant was obtained, which was not lysed by either 195/5 or 159/3. This variant is referred to as A"B " . Figure 2 summarizes the results of the lysis asεays, leading to isolation of the variants. Example 2 It was of interest to determine the pattern of HLA expression of variant A " B " . The patient from whom parent line LB33-MEL was derived was typed as HLA-A24, A28, B13, B44, Cw6, Cw7. When PCR expression analysiε was carried out, it was found that both LB33-MELcl, and the B " variant express all six alleles; however, the A-B " variant does not expresε HLA-A28, B44, and Cw7. As a result, it was concluded that one of these HLA molecules presents the antigen leading to lysiε by CTLs. The following example explores this further. Example 3 Samples of the A " B " variant were transfected by plasmid pcDNA-I/AmpI which had cloned therein, one of HLA-A28, HLA- B44, or HLA-CW7. Following selection, the cells were tested SUESTlTUTi HEET (RUL 25 in a TNF release assay, following Traverεari, et al. , Immunogenetics 35: 145-152 (1992), incorporated by reference herein. The resultε are εummarized in figure 3, which shows that HLA-B44 is clearly implicated in the presentation of the antigen. Example 4 Once the presenting HLA molecule waε identified, studieε were carried out to identify the molecule, referred to hereafter as the "tumor rejection antigen precursor" or "TRAP" molecule which was the source of the presented peptide. To do this, total mRNA was isolated from cell line LB33- MELcl. The mesεenger RNA waε isolated using an oligo-dT binding kit, following well recognized techniques. Once the messenger RNA was secured, it was tranεcribed into cDNA, again using standard methodologieε. The cDNA waε then ligated to EcoRI adaptorε and cloned into the EcoRI εite of plasmid pcDNA-I/Amp, in accordance with manufacturer's instructionε. The recombinant plasmids were then electrophorated into DH5 E. coli (electroporation conditions: 1 pulse at 25 μfarads, 2500 V) . The transfected bacteria were selected with ampicillin (50 μg/ml), and then divided into poolε of 100 bacteria each. Each pool represented about 50 different cDNAs, as analysiε showed that about 50% of plasmidε contained an insert. Each pool was amplified to saturation, and plasmid DNA was isolated via alkaline lysis, potassium acetate precipitation and phenol extraction, following Maniatis et al., in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, N.Y., 1982). Cesium gradient centrifugation was not used. The amplified plasmids were then transfected into eukaryotic cells. Samples of COS-7 cells were εeeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbeco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 μl/well of DMEM medium containing 10% Nu serum, 400 μg/ml DEAE-dextran, 100 μM chloroquine, and 100 ng of a plasmid containing cDNA for HLA-B44 from LB33. Following four hours of incubation at 37°C, the medium was removed, and replaced by 50 μl of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200 μl of DMEM supplemented with 10% of FCS. Following this change in medium, COS cells were incubated for 48 hours at 37°C. Medium waε then diεcarded, and 2000 cells of 159/5 were added, in 100 μl of Iscove'ε medium containing 10% pooled human εerum and 25 U/ml IL-2. Supernatant waε removed after 24 hourε, and TNF content waε determined in an aεεay on WEHI cellε, as described by Traversari et al., Immunogeneticε 35: 145-152 (1992), the diεclosure of which is incorporated by reference. One pool stimulated TNF release above background, and these bacteria were cloned, and used in the following experiment. Example 5 Plasmid DNA was extracted from the bacteria cloned in Example 4, transfected into a new sample of COS cells in the same manner as described εupra. and the cells were again tested for stimulation of 159/5. A positive clone was found in clone 350/2, aε demonstrated by data summarized in figure 4A. In order to confirm the results obtained to this point, the human choriocarcinoma cell line JAR, which is readily available from the American Type Culture Collection, was used. This cell line doeε not expreεε HLA moleculeε, nor iε it recognized by CTL 159/5. When JAR was transfected with HLA- B44 cDNA, it was still not recognized by CTL 159/5. Co- transfection with HLA-B44 and 350/2 cDNA , however, led to lysis, as is seen in figure 4B. The plasmid from the positive clone was removed, and sequenced following art known techniques. Information shows that the plasmid insert was 1896 base pairs long, and showed no homology with any sequences in data banks. The nucleotide sequence is set forth herein as SEQ ID NO: 1. Example 6 In order to ascertain the peptide which was the tumor rejection antigen, fragments of SEQ ID NO: 1, averaging about 300 base pairs, were amplified via PCR, cloned into pcDNAI/Amp, and then cotransfected into COS cells with plasmid encoding HLA-B44, following the protocols of the preceding examples. These experiments led to identifying the region corresponding to amino acid residues 683-955 of SEQ ID NO: 1 as encoding the antigenic peptide. This region was compared to the peptide described by Khanna, et al., J. Exp. Med. 176: 169-176 (7/92), and the peptide described in Serial No. 08/233,305, filed April 26, 1994, i.e.: Glu Glu Lys Leu lie Val Val Leu Phe corresponds to these residues. As such, a peptide corresponding to this εequence was synthesized, and used to sensitize HLA-B44 + cell lines. The results are shown in figures 6A and 6B, which depict the results of a 51 Cr release assay using EBV transformed B cells (figure 6A) , and the B" variant described supra (figure 6B) . The cells were incubated with varying concentrationε of the peptide for 30 minutes at 37°C, before adding CTL 159/5 (effector/target ratio: 10:1). Half maximal lysis was obtained with 100-200 ng/ml of peptide. Example 7 Examples 1-6, set forth supra, describe work using the cell line LB33-Melcl. Additional cell lines were also derived from a cutaneous metastasis from patient LB33. One such line is LB33-MEL.A-1, which is used in the example which follows. First, the cell line was used, in the same manner that the cell line of examples 1-6 waε used (Herin et al. , supra1. Blood mononuclear cells (10 6 /well), were stimulated with irradiated tumor cells (3/10 5 cells/well), in 2 ml of Iεcove'ε medium, supplemented with 10% pooled human serum, asparagine- glutamine-arginine (36 mg/ml, 216 mg/ml, 116 mg/ml, respectively), 2-mercaptoethanol (0.05 mM) , and 5 U/ml of human IL-4. IL-2 (10 U/ml) was added on the third day of cultivation. Sensitivity of the tumor cellε to autologouε CTLs was determined as in example 1, supra. The experiment yielded 82 stable cytolytic T lymphocytes, derived from seven independent cultureε. All of theεe CTLε were CD8 + . They were εpecific for tumor cells in that they lysed LB33-MEL.A-1 cells, but not K562, or autologous, EBV transformed cells. Example 8 The fact that LB33-MEL.A-1 cells were lysed by autologouε CTLs εuggested the next experiment, which was to identify the antigens recognized by establishing antigen loss variantε. To do this, samples of the cell line were selected, four times, with the autologous CTL clone LB33-CTL 159/3, described supra. Each round of selection involved incubating, for 2-6 hours, 2-3xl0 7 adherent tumor cells with a similar number of CTLs, in the same manner deεcribed εupra. In each round, CTLs were washed away following the incubation, and the surviving adherent tumor cells were amplified prior to the next round of εelection. Thiε procedure reεulted in a clone resistant to CTL 159/3; however, when tested with additional autologous CTLs, it was found that CTL 159/5, described supra, did lyse the loss variant, as did additional CTL clones, including 204/26, and 202/1. Please see figure 6, the column labelled "MEL.A- 1.1". Similarly, additional cell lines were established which were not lysed by one of these four CTL clones, but was lysed by the others. Note figure 6. Thus, at least four different antigens were found to be presented on the surface of LB33- MEL.A-1, because four distinct antigen-loss variants were identified. As set forth in figure 6, then, LB33-MEL.A-1 is considered "A + B + C + D + " for antigen expression (lysed by all of CTL 159/3, 159/5, 204/26, and 202/1); MEL.A-1.1 is A " B + C + D + (not lyεed by 159/3, lyεed by otherε); MEL.A-1.2 is A + B ~ C + D + (not lysed by 159/5; lysed by others), MEL.A-1.3 is A + B + C " D + (not lysed by 204/26; lysed by others), and MEL.A-1.4 iε A"B + C + D" (not lyεed by 202/1 or 159/3). Further, cell line MEL.A-1.1.1 waε isolated, which was A " B " C + D " (lysed only by 204/26). When the 82 CTLs identified via example 7 were tested on these lines, 29 anti-A, 29 anti-B, 10 anti-C, and 14 anti-D clones were identified, suggesting that there were no other antigens being presented. Selection with anti-D CTL clone 202/1 led to identification of a line which was also resistant to the anti- A CTL clone (159/3), as did selection with anti-B CTL (i.e., the resulting A " B ~ C + D " line). This result suggests that A " D ~ and A"B " D " antigen loss variants were actually HLA loss variants, with antigens A, B and D sharing the same HLA presenting molecule, or that different class I molecules had been lost together with the antigen loεs variants. The following experiments pursued this issue. Example 9 The patient from whom the LB33 cell lines had been developed had been serologically typed, previously, as HLA- A24, A28, B13, B44, Cw6, Cw7. Studies were then carried out to determine the expresεion of HLA class I genes by the cell lines. Semi-quantitative conditions for DNA amplification by PCR were established in order to asεess the expreεεion of each of the six class I alleles by the different LB33-MEL tumor cell clones. The Amplification Refractory Mutation System (ARMS) PCR methodology propoεed by Browning et al , that relies on the perfect nucleotide matched needed at the 3' end of primers to ensure specificity of DNA amplifications was used. See Browning et al, Proc. Natl. Acad. Sci. USA 90: 2842 (1993) incorporated by reference herein. On the basiε of sequences obtained in typing LB33, alleles-εpecific primerε that enabled us to discriminate each of the six alleles from the five others (5' primer followed by 3' primer) were synthesized. for A24: 5'-GCCGGAGTATTGGGACGA and 5'-GGCCGCCTCCCACTTGC, (SEQ. ID. NO. 5 and 6) for A28: 5'-GGAGTATTGGGACCGGAAG and 5'-GGCCGCCTCCCACTTGT, ( SEQ . ID . NO . 7 and 8 ) for B13: 5'-CGCCACGAGTCCGAGGAT and 5'-CCTTGCCGTCGTAGGCTA, (SEQ. ID. NO. 9 and 10) for B44: 5'-CGCCACGAGTCCGAGGAA and 5'-CCTTGCCGTCGTAGGCGT, (SEQ. ID. NO. 11 and 12) for Cw6: 5'-CCGAGTGAACCTGCGGAAA and 5'-GGTCGCAGCCATACATCCA, (SEQ. ID. NO. 13 and 14) for Cw7: 5'-TACAAGCGCCAGGCACAGG and 5-CTCCAGGTAGGCTCTGTC, (SEQ. ID. NO. 15 and 16) To carry out semi-quantitative measurementε of expression, 27 cycles of PCR amplification of reverse transcribed RNA were carried out with each set of primers and DNA amplification was found to be in the linear range obεerved. The quantity of the amplified DNA waε visually asεeεsed with agarose gelε stained with ethidium bromide. These quantities were compared to those obtained with a standard curve containing the products of RT-PCT amplification of serial dilutions of RNA from LB33- MEL.A-1 cells. The expression of samples was normalized for RNA integrity by taking into account the expression level of the β-actin gene. The results were expressed relative to the level of expreεsion by LB33-MEL.A-1 cells. The results of this work are set forth in Table 1, which follows. A "+++" indicates expresεion corresponding to more than half that of the LB33-MEL.A-1 cells, "++" means that expression was between 1/8 and 1/2 of that of LB33-MEL.A-1, a "+" means that expression waε less than 1/8 of that of LB33-MEL.A-1 expressed and "-" means there was no expression. Table 1. Expression of HLA class I by the antigen-loss variants derived from LB33-MEL.A-1 cells- LB33-MEL.A tumor cells LB33- MEL.A- ■ 1 Antigen-loss variantε Expression Of A " B " c- A"D " A-B-D " A. Gene expression A24 +++ +++ +++ - ++ +++ A28 +++ +++ +++ +++ + - B13 +++ +++ +++ + +++ +++ B44 +++ +++ +++ +++ ++ - Cw6 +++ +++ +++ + +++ +++ Cw7 +++ ++ +++ +++ + — Aε seen, both MEL.A-1 cells, and B " variant expressed similar levels of all six HLA alleles. The A " variant showed an approximate 4-fold decrease in expreεεion of Cw7. The remaining antigen loss variants showed decreases in expression of sets of three alleles. For C " cells, reduced levels of expresεion for HLA-A24, B13, and Cw6 were found, while A"D", and A"B"D" variants showed reduction in A28, B44, and Cw7 expresεion. This suggests that A24-B13-CW6, and A28-B44-Cw7 constitute two HLA class I haplotypes of patient LB33, and that reduced expreεsion of these haplotype probably accounted for loss of antigen expreεsion by the i munoselected tumor cells. Example 10 The next experiments were designed to confirm a correlation between HLA gene expression, and lysis by CTLs. To do this, the expreεεion of a given HLA gene, aε determined supra, was compared with the results obtained using a standard antibody assay. Only A24, A28 and B13 were tested, using murine antibodies specific thereto (C7709A1 for A24; 2.28M1 for A28, and Tϋ 48 for B13). Binding of antibody was determined by incubation with antibody, washing and then contacting with goat anti-mouse Ig antibodies, coupled to fluorescein. The cells were then analyzed by flow cytometry, a standard technique. Table 2 summarizes the results, which are also shown in figure 7. In table 2 that follows, the indicated level of HLA expression corresponds to the mean intensity of fluorescence shown in figure 6. Values are expressed relative to levels found in LB33-MEL.A-1 cells. It appears from these resultε that when levels of HLA expression estimated to range below 1/8 of that of LB33-MEL.A- 1 cells, undetectable or barely detectable levels of HLA surface molecules are found, thus suggesting that antigen presentation to CTL was unlikely for the given HLA molecule. In view of this, and assuming that C " , A"D" and A'B'D" selected cellε had lost expression of antigen because of lack of HLA molecules, it appeared to be the case that the class I presenting molecules for antigen A were A28 or Cw7, B44 for antigen B, A24 or B13 or Cw6 for antigen C, and A28 or Cw7 for antigen D. Table 2 LB33-MEL.A-1 Antigen-loss variants Expression of B- AD " A-B " D " Expression of surface antigen A24 100 33 13 4 41 95 A28 100 29 14 3 1 1 B13 100 27 22 1 40 230 Example 11 The experiments detailed above were followed by additional work to determine, definitively, the presenting molecules for the antigens expressed by the LB33-MEL.A cells. To do this, tumor cells which had lost expression of particular HLA clasε I molecules were transfected, using the classic calcium phosphate precipitation method, with expression vector pcDNA3, into which the particular class I cDNA was cloned. This vector contains the neo R marker. Transfectants were selected with 1.5 mg/ml of G418, and were then used to stimulate CTL clones, using the TNF asεay set forth in the previous examples. Figure 8 depicts these resultε. Expression of antigen B was restored in A ~ B ~ D ~ cells by transfection with a plasmid carrying HLA-B44, but not with plasmids containing HLA-A28 or HLA-Cw7. The expression of antigen C was restored in C " cells by transfection with HLA B13. Four other anti-C CTL clones also recognized C " cellε, but five other anti-C CTL cloneε, including depicted CTL 179C/50, did not; rather, theεe CTLε recognized C " cells transfected with HLA-Cw6. Thus, it may be concluded that there are two groups of anti-C CTL clones. One recognizes an antigen presented by HLA-B13, and the other an antigen presented by HLA-Cw6. Aε for antigen D, A ~ D ~ cells were restored to A " D + via transfection with HLA-A28. None of the cDNA restored expression of antigen A (i.e., tested HLA A28, B44, Cw7) , although it clearly is preεented by HLA-claεε I molecules, because lysis by anti-A CTLs is completely inhibited by anti-clasε I monoclonal antibody W6/32. It is possible that this antigen may be presented by a non-A, B, C class I molecule, of which two alleleε were preεent in patient LB33, one of these being lost, together with the A28-B44-Cw7 haplotype in A " D " , A ~ B ~ D ~ cellε. The results for antigen C have led to a change in nomenclature. There are two antigens referred to as antigen, Ca and antigen Cb, hereafter. Example 12 In further experiments, the question of whether or not cells of the line LB33-MEL.B could be recognized by autologous cell lines, was addresεed. Irradiated LB33-MEL.B.1 cellε were uεed in the same manner as was used, supra (Herin, et al), to stimulate autologous lymphocytes. The lymphocytes had been taken from patient LB33 in 1990 or 1994. Aε iε εhown in figure 9, only the lymphocytes from 1994 lysed LB33-MEL.B-1 cellε; however, they did not lyεe LB33- MEL.A cellε. Thuε, the LB33-MEL.B-1 line presents an antigen not found on LB33-MEL.A. The experiments described herein parallel thoεe deεcribed εupra and, as in the prior experiments, another panel of CD8 + CTL clones were established. The panel of reactivity of CTL 269/1 is shown in figure 10A. Note reaction with "MEL.B-1", but not "MEL.A-1". The new antigen defined thereby is referred to aε LB33-E. In antibody inhibitory experiments, mAbs to HLA-A24 inhibited lyεis. This is εhown in figure 10B. Hence, the "E" antigen is presented by HLA-A24. The foregoing experiments describe isolated nucleic acid molecules coding for a tumor rejection antigen precursor, a "TRAP" molecule. The protein molecule for which these code is processed intracellularly in a manner which leads to production of at least one tumor rejection antigen, or "TRA", which is presented by HLA-B44 molecules. While it has been obεerved previouεly that HLA-B44 moleculeε present peptides derived from tyrosinase, the nucleic acid molecules of the invention do not code for tyrosinase, and the TRAs are not tyrosinaεe derived. The tumor rejection antigenε of the invention are isolated nonapeptides which have a Glu residue at the 2nd position, and a Phe residue at the 9th position. Especially preferred is the nonamer of SEQ ID NO: 2, i.e.: Glu Glu Lyε Leu lie Val Val Leu Phe. Alεo useful are nonapeptides which, in addition to the required residues at positions 2 and 9, have one or more of the following defined residues: position 1: Glu position 3: Lys position 4: Leu position 5: He position 6: Val position 7: Val position 8: Leu The peptides of the invention are similar to the peptide disclosed in Serial No. 08/233,305, so-assigned to the assignee of the subject application, i.e.: Ser Glu He Trp Arg Asp He Asp Phe (SEQ ID NO: 3) Khanna, et al., supra, teaches a decamer, i.e.: Glu Glu Asn Leu Leu Asp Phe Val Arg Phe (SEQ ID NO: 4) but does not discuss how modification of the decamer could lead to an effective nonamer. The invention thus involves isolated nucleic acid molecules which code for a tumor rejection antigen precursor, or "TRAP" , with the proviso that the TRAP is not tyrosinase such aε, but not being limited to, SEQ ID NO: 1 and nucleic acid molecules which code for a tumor rejection antigen precursor processed to at least one antigen presented by HLA- B44, which hybridize to the molecules of SEQ ID NO: 1 under stringent conditions, such aε 3.5xSSC, lxDenhardt'ε solution, 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, and 2 mM EDTA for 18 hours, followed by four washes at 65°C for 20 minutes in 2xSSC ; 0.1% SDS, and one wash of up to 20 minutes in O.δxSSC, 0.1% SDS. Other conditions, reagents, and so forth will result in the same, or greater stringency, as one of ordinary skill in the art will know. The TRAP coded for is one which is procesεed to several tumor rejection antigens, or TRAs, which are presented by HLA molecules on cell surfaceε. The presenting HLA molecules include HLA-A24, HLA-A28, HLA- B13, HLA-B44, and HLA-Cw6. The nucleic acid molecules of the invention may be, e.g., genomic DNA, ("gDNA"), complementary DNA ("cDNA"), or a form of RNA. The invention also involves isolated nucleic acid molecules which are complementary to the molecules described above. An especially preferred form of the invention are molecules which contain the sequence set forth in SEQ ID NO: l. Also encompassed by the invention are vectors which contain the nucleic acid moleculeε of the invention, operably linked to a promoter. The vectorε may alεo include a molecule coding for the preεent HLA molecule. Aε theεe two moleculeε, i.e., the HLA molecule and the TRAP, are neceεεary to generate a cytolytic T cell response, the invention also encompasεeε expreεεion εyεtems where nucleic acid molecules coding for TRAP and for the HLA molecule are presented as εeparate portionε in, e.g., a kit. The invention alεo encompaεεes cell lines tranεfected by the vectorε deεcribed herein, be these prokaryotic cells, such as E. coli, or eukaryotic cellε, εuch as Chinese hamster ovary ("CHO") or COS cells. As indicated, the complexes of TRA and HLA molecule provoke a cytolytic T cell responεe, and as such isolated complexes of the tumor rejection antigen and an HLA molecule are also encompaεεed by the invention, aε are iεolated tumor rejection antigen precursors coded for by the previously described nucleic acid molecules. In each case, supra , "HLA" means, e.g, HLA-A24, HLA-A28, HLA-B13, HLA-B44, and HLA-Cwδ. The invention as described herein has a number of uses, some of which are described herein. First, the identification of a tumor rejection antigen which iε specifically presented by an HLA molecule, aε well aε a nucleic acid molecule coding for itε parallel tumor rejection antigen precurεor permitε the artiεan to diagnoεe a diεorder characterized by expreεsion of the TRAP. These methods involve determining expression of the TRAP gene, and/or TRAs derived therefrom, such as TRA presented by HLA molecules. Other TRAs may also be derived from the TRAPε of the invention and presented by different HLA moleculeε. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or asεaying with labelled hybridization probeε. In the latter situation, assaying with binding partners for complexes of TRA and HLA, such as antibodies, is especially preferred. The isolation of the TRAP gene also makes it posεible to isolate the TRAP molecule itself, especially TRAP molecules containing the amino acid sequence of SEQ ID NO: 1. Fragments of peptideε of theεe iεolated moleculeε when preεented aε the TRA, or as complexes of TRA and HLA, such as A2, A28, B13, B44, and Cw6, may be combined with materials such as adjuvants to produce vaccineε uεeful in treating disorders characterized by expresεion of the TRAP molecule. In addition, vaccineε can be prepared from cellε which preεent the TRA/HLA complexeε on their surface, such as non-proliferative cancer cells, non- proliferative transfectants, etcetera. In all cases where cells are used aε a vaccine, these can be cells transfected with coding sequenceε for one or both of the componentε necessary to prove a CTL response, or be cells which expresε both molecules without tranεfection. Further, the TRAP molecule, its associated TRAs, as well as complexes of TRA and HLA, may be used to produce antibodies, using standard techniques well known to the art. When "disorder" is used herein, it refers to any pathological condition where the tumor rejection antigen precursor is expressed. An example of such a disorder is cancer, melanoma in particular. Therapeutic approaches based upon the diεcloεure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as cellε presenting the relevant HLA molecule. One such approach is the administration of CTLs εpecific to the complex to a subject with abnormal cells of the phenotype at isεue. it iε within the εkill of the artiεan to develop such CTLs in vitro. Specifically, a sample of cells, such as blood cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, εuch as a COS cell of the type described supra. These transfectants preεent the deεired complex on their εurface and, when combined with a CTL of intereεt, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells. To detail the therapeutic methodology, referred to as adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986); Reddel et al., Science 257: 238 (7-10-92); Lynch et al. , Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al. , Cell 59: 603- 614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal. The foregoing therapy assumes that at least some of the subject'ε abnormal cells present the HLA/TRA complex. This can be determined very eaεily, aε the art iε very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expresεing DNA containing the indicated sequences. Once isolated, εuch cellε can be used with a sample of a subject's abnormal cells to determine lysis in vitro. If lysis is observed, then the use of specific CTLs in such a therapy may alleviate the condition associated with the abnormal cellε. A less involved methodology examineε the abnormal cellε for HLA phenotyping, using standard asεays, and determines expression via amplification using, e.g., PCR. Adoptive transfer iε not the only form of therapy that iε available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach, i.e., the use of non-proliferative cells expresεing the complex, has been elaborated upon supra. The cells used in thiε approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., Proc. Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplifies this approach, showing the use of transfected cellε expreεεing HPVE7 peptides in a therapeutic regime. Various cell types may be uεed. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. In these syεtems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materialε de facto "infect" host cells. The cells which reεult preεent the complex of interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining the tumor rejection antigen or the precursor itself with an adjuvant to facilitate incorporation into cells which present the HLA molecule of interest. The TRAP iε proceεεed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing. Other aspectε of the invention will be clear to the εkilled artiεan and need not be repeated here. The termε and expreεεions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such termε and expressions of excluding any equivalentε of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention. (1) GENERAL INFORMATION: (i) APPLICANTS: Coulie, Pierre; Boon-Falleur, Thierry (ii) TITLE OF INVENTION: Isolated Nucleic Acid Molecules Which Codes For A tumor Rejection Antigen Precursor Which Is Procesεed To An Antigens Preεented By HLA Molecules, And Useε Thereof (iϋ) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Felfe & Lynch (B) STREET: 805 Third Avenue (C) CITY: New York City (D) STATE: New York (F) ZIP: 10022 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diεkette, 5.25 inch, 360 kb εtorage (B) COMPUTER: IBM (C) OPERATING SYSTEM: PC-DOS (D) SOFTWARE: WordPerfect (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 08/373,636 (B) FILING DATE: 17-JANUARY-1995 (C) CLASSIFICATION: 435 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/253,503 (B) FILING DATE: 3-JUNE-1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Hanεon, Norman D. (B) REGISTRATION NUMBER: 30,946 (C) REFERENCE/DOCKET NUMBER: LUD 5378.2 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 688-9200 (B) TELEFAX: (212) 838-3884 (2) INFORMATION FOR SEQ ID NO: 1 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1896 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: GCGGCGGTGG CGGAGGCGGA CACATTGGCG TGAGACCTGG GAGTACGTTG TGCCAAATCA 60 TTGCCACTTG CCACATGAGT GTAAATGATG GCGGATGCAA GTATGTCCTC TGCCGATGGG 120 AAAAGCGATT ATGGCCTGCG AAGGTGACAG CCATTATTCT GTAACTTCAG GACTTAGAAA 180 TGACTTTCGG GTGACAAGTA AAATCTTGAT CAGGAGATAC CTAGGATTTG CTTCAGTGAA 240 ATAATTGAGC CAGAACACGG TTGGCACTGA TTCTCGTTCC CCATTTAATG GGGTTTTGGT 300 CTAGTGCTTC CAAGGTTACA CTTCCAGAAA TGTCTTTTTT TTTTCACACT AAAAAAAAAA 360 AAAAGAATCA GCTGTAAAAA GGCATGTAAG GCTGTAACTC AAGGAAAGAT CTGGCAAGCA 420 GCCCTGTGAT AGTAAATTAT GGTCGTGTTC AGGGAATGCT TTCCAGCAAT TCAGTAGACA 480 GTGCTCAGCT GCAATGCAAA AGCCCAGGTC CTTGTCTTTG TCTGCCACTG GCCTCTCATG 540 CCTCAGTTTC CCCATCTGTG AAACAATGGG GATTGGACCA AATATCTGAA ATCCCATGGT 600 TATAGGCCTT CAGGATTACC TGCTGCATTT GTGCTAAAGT TTGCCACTGT TTCTCACTGT 660 CAGCTGTTGT AATAACAAGG ATTTTCTTTT GTTTTAAATG TAGGTTTTGG CCCGAACCGC 720 GACTTCAACA AAAAATAAGA GAAGAAAGGA ATATTTTCTA GCTGTGCAAA TCCTCTCCCT 780 AGAGGAAAAG TTAATTGTTG TGTTGTTTTA ATACTGTTTT TTCCCGTGTA GATTTCTGAT 840 ACTTCAATCC CCTACTCCCC CAAAACAGTT GAAGCCCAGC CCACTCTTAA TGGGCTTATT 900 CACCATTTGT GTAATTCATT AATGCTCATA ATAACCTCAT GAGAAAGCAA CTAGTTTGAT 960 TTTATGTCAG TTTGGAAGCT GAAGATCCAA ACGAGGCATT CTGTGAGATC TATGGAGAGA 1020 TTGGTACAAA CACTGAATAC ATGTAAATTA TACTCAGGGT AGACCCTATT TGTGGTTAAA 1080 ATAGGGATAT TTCCTTTTTT TTTTTTTTTT TTTTGACTGT TTCTTAATCA GTGCCATGCC 1140 AGGAAAATAG GGATGTTTCC TTCCCAGAGA TCTGTGTGTC TTTTTTCAGA AACGTCTGTG 1200 ACAGGCCCAT CAATTTTGAA ATATTTGGTT TTTGAGCCTG TCACTCTAAA CCAGCGTTTA 1260 ACGTTCAAAA GGCAAATAAC TGATGACCAG GCGGCACATT GTTCTGCTCC GTGAGTGTCT 1320 GGCACTGGGA AAGGTGTAGA TTGTCTAGAA TGACAGCAAT TCCGACGCCC CAGTCAGTCC 1380 TGCGTGATTG TGGCGAGGGC GCGTCTGGCA CCGGGAAGGT GTAGATCATC TAGAATGACG 1440 GCGATTCCGA CGCCCCGGTC AGTCCTGCGT GATTGGCGAG GGTGCATCTG TCGTGAGAAT 1500 TCCCAGTTCT GAAGAGAGCA AGGAGACTGA TCCCGCGTAG TCCAAGGCAT TGGCTCCCCT 1560 GTTGCTCTTC CTTGTGGAGC TCCCCCTGCC CCACTCCCTC CTGCCTGCAT CTTCAGAGCT 1620 GCCTCTGAAG CTCGCTTGGT CCCTAGCTCA CACTTTCCCT GCGGCTGGGA AGGTAATTGA 1680 ATACTCGAGT TTAAAAGGAA AGCACATCCT TTTAAACCAA AACACACCTG CTGGGCTGTA 1740 AACAGCTTTT AGTGACATTA CCATCTACTC TGAAAATCTA ACAAAGGAGT GATTTGTGCA 1800 GTTGAAAGTA GGATTTGCTT CATAAAAGTC ACAATTTGAA TTCATTTTTG CTTTTAAATC 1860 CAGCCAACCT TTTCTGTCTT AAAAGGAAAA AAAAAA 1896 (2) INFORMATION FOR SEQ ID NO: 2 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: amino acid reεidueε (B) TYPE: 9 amino acidε (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2 Glu Glu Lyε Leu He Val Val Leu Phe 5

Claims: We claim : 1. Isolated nucleic acid molecule which codes for a tumor rejection antigen, consisting of the nucleotide sequence of SEQ ID NO: 1. 2. Isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of SEQ ID NO: 1, under stringent conditions. 3. The iεolated nucleic acid molecule of claim 2, wherein said nucleic acid molecule is cDNA. 4. The isolated nucleic acid molecule of claim 2, wherein said nucleic acid molecule iε genomic DNA. 5. Recombinant vector compriεing the nucleic acid molecule of claim 1, operably linked to a promoter. 6. Recombinant vector comprising the nucleic acid molecule .of claim 2, operably linked to a promoter. 7. Cell line or bacterial strain transformed or transfected positively with the isolated nucleic acid molecule of claim 1. 8. Cell line transformed or transfected with the iεolated nucleic acid molecule of claim 2. 9. Cell line tranεformed or tranεfected with the recombinant vector of claim 5. 10. Cell line tranεformed or tranεfected with the recombinant vector of claim 6. 11. Isolated tumor rejection antigen precursor coded for by the nucleic acid molecule of claim 1. 12. Isolated nonapeptide having Glu at position 2 and Phe at position 9. 13. Isolated peptide consisting of amino acid sequence Glu Glu Lys Leu He Val Val Leu Phe. 14. Immunogenic composition comprising the isolated peptide of claim 12 or 13, and an adjuvant. 15. Isolated cytolytic T cell line which is specific for a complex of the peptide of claim 12 or 13 and an HLA-B44 molecule. 16. Method for determining a cancerous condition in a patient of type HLA-B44, comprising assaying a sample of cells to determine expresεion of the nucleic acid molecule of claim 2, wherein expreεεion of εaid nucleic acid molecule iε indicative of a cancerouε condition. 17. The method of claim 16, comprising contacting said sample with the isolated nucleic acid molecule of SEQ ID NO: 1.

Inventors: BOON-FALLEUR THIERRY, COULIE PIERRE, BOON-FALLEUR, THIERRY, COULIE, PIERRE
Applicants: LUDWIG INST CANCER RES, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 1995
Main classification: C12Q1
IPC codes: A61K35, A61K39, A61P35, C07H21, C07K7, C07K14, C12N1, C12N5, C12N15, C12P21, C12Q1, C12R1, G01N33